Abstract:Objective:This study was designed to investigate the effects of ubenimex,a CD13 inhibitor,(ubenimex alone and ubenimex with cisplatin),on A549 cell proliferation and apoptosis.This study also aimed to determine the possible underlying mechanisms.Methods: A549 cells were cultured in RPMI 1640 medium supplemented with 10%fetal bovine serum.The cultured cells were then treated with ubenimex at varying concentrations or a combination of ubenimex(100μg·mL~(-1)) and cisplatin at varying concentrations.Methyl thiazolyl tetrazolium assay was used to determine the cell proliferation ratio.Flow cytometer was then used to analyze the cell apoptotic rates (AnnexinV-FITC/PI double-staining).The protein expressions of p53,Bcl-2,and Bcl2-xL,as well as the cleavage of PARP-1 and caspase were determined through Western blot.Spectrophotometrical assay was performed using alanine-p-nitroanilido as a substrate to detect CD13 activity.Hochest 33342 staining combined with flow cytometry analysis was performed to detect the side population(SP) cells in A549 cells. Results:Ubenimex alone did not significantly inhibit A549 cell proliferation(P>0.05).By contrast,ubenimex significantly increased the chemosensitivity of A549 cells to cisplatin at 8μM or 16μM in a time-dependent manner.After the A549 cells were treated with different concentrations of cisplatin(i.e.,8,16,32,and 64μM) and ubenimex(100μg·mL~(-1)) for 24,48,and 72 h,the cell proliferation ratios were obtained.In particular,at a cisplatin concentration of 8 uM,the cell proliferation ratios of the cisplatin group against the combined treatment of cisplatin with ubenimex(100μg·mL~(-1)) were 89.44±15.84%versus 62.18±5.35%(24 h),64.81±5.86%versus 33.09±3.14%(48 h),and 62.06±7.6%versus 27.92±5.84%(72 h).At 16μM of cisplatin,the cell proliferation ratios(cisplatin against the combined treatment) were 84.61±3.73%versus 54.50±4.22%(24 h),22.09±5.74%versus 3.62±3.28%(48 h),and 19.22±1.57%versus 0.67±0.42%(72 h).Ubenimex did not significantly increase the chemosensitivity of A549 cells to cisplatin(64μM).Cellular apoptotic rates were also significantly increased in the combined treatment group[cisplatin(16μM) and ubenimex]compared with that in the cisplatin group alone.Ubenimex alone cannot change the protein expression of p53,Bcl-2,and Bcl2-xL,as well as the cleavage of PARP-1 and caspase.By contrast,ubenimex can significantly inhibit the CD13 activity of A549 cells and decrease the percentage of SP cells of A549 cells(P<0.05).Conclusion:Ubenimex can significantly enhance the chemosensitivity of low-dose cisplatin on A549 cells in vitro.Therefore,ubenimex may be used as a sensitizer of cisplatin for human non-small cell lung cancer with CD13 expression.

Epigenetic Mechanism of Enrichment of A549 Lung Cancer Stem Cells with 5-Fu

FUT4siRNA Augments the Chemosensitivity of Non-Small Cell Lung Cancer to Cisplatin Through Activation of FOXO1-induced Apoptosis.

5-Fluorouracil Nanoparticles Inhibit Hepatocellular Carcinoma Via Activation of the P53 Pathway in the Orthotopic Transplant Mouse Model

MFAP5 Strengthened the Stem Cell Features of Non-small Cell Lung Cancer Cells by Regulating the FBW/Sox9 Axis

Super enhancer-LncRNA SENCR promoted cisplatin resistance and growth of NSCLC through upregulating FLI1

Induced Pluripotent Stem Cell-Related Genes Influence Biological Behavior and 5-Fluorouracil Sensitivity of Colorectal Cancer Cells

Overexpression of long noncoding RNA LINC01419 in esophageal squamous cell carcinoma and its relation to the sensitivity to 5-fluorouracil by mediating GSTP1 methylation

Sulforaphane epigenetically demethylates the CpG sites of the miR-9-3 promoter and reactivates miR-9-3 expression in human lung cancer A549 cells

Upregulation of Microrna-451 Increases Cisplatin Sensitivity of Non-Small Cell Lung Cancer Cell Line (A549)

Synergistic eradicating impact of 5-fluouracil with FeO nanoparticles-diethyldithiocarbamate in colon cancer spheroids

The Methylation Status of ABCC8, CHFR, BMP3B, LOX, PRSS21, RASSF1A Promoters Correlate with the Sensitivity of Three Breast Cancer Cell Strains to 5-FU.

Effects of Ubenimex,a CD13 Inhibitor,on the Chemosensitivity of A549 Cells to Cisplatin

Curcumin enhances cisplatin sensitivity of human NSCLC cell lines through influencing Cu-Sp1-CTR1 regulatory loop

Enhanced Cisplatin Cytotoxicity by RNA Interfering the Excision Repair Cross-complementing Gene 1 in Lung Cancer Cell A549/DDP

Effect of Nano-Platinum on Proliferation and Apoptosis of Non-Small Cell Lung Cancer Cells via P53 Pathway

Effect of m6A Methylation Modification on IncRNA ENST00000425005 in Doxorubicin Resistance and Epithelial-Mesenchymal Transition Progression in Lung Cancer Cells

Less Cytotoxicity to Combination Therapy of 5-Fluorouracil and Cisplatin Than 5-Fluorouracil Alone in Human Colon Cancer Cell Lines.

In Vitro Additive Antitumor Effects of Dimethoxycurcumin and 5‐fluorouracil in Colon Cancer Cells

Coexpression of Two Closely Linked Avian Genes for Purine Nucleotide Synthesis from a Bidirectional Promoter:

Arsenic sulfide reverses cisplatin resistance in non‐small cell lung cancer in vitro and in vivo through targeting PD‐L1

Folate-modified liposomes mediate the co-delivery of cisplatin with miR-219a-5p for the targeted treatment of cisplatin-resistant lung cancer